This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
A signed written informed consent is required before performing any study-related operations
Age greater than or equal to 18 years old
Histologically or cytologically confirmed locally advanced/metastatic, unresectable non-squamous NSCLC with KRAS p. G12C mutation confirmed by the central lab
No history of systemic anticancer therapy to the local advanced/metastatic disease
Previous (≤2 years) or current solid tumors or hematologic tumors of other pathological types
Carry other driver gene mutations with available target therapy, or carry other KRAS mutations
Subjects with untreated central nervous system (CNS) metastases were excluded;
Uncontrolled pleural effusion, pericardial effusion, and ascites
Allist Pharmaceuticals, Inc.
Lead sponsor